Blood Res 2017; 52(3): 193-199  https://doi.org/10.5045/br.2017.52.3.193
Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma
Hyun-Young Kim1,2, Mi-Ae Jang3, Hee-Jin Kim1, Seok Jin Kim4, Won Seog Kim4, Sun-Hee Kim1
1Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 2Department of Laboratory Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, 3Department of Laboratory Medicine and Genetics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, 4Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Correspondence to: Sun-Hee Kim, M.D., Ph.D.Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, KoreaE-mail: sunnyhk@skku.edu
Received: April 3, 2017; Revised: June 2, 2017; Accepted: June 17, 2017; Published online: September 30, 2017.
© The Korean Journal of Hematology. All rights reserved.

Abstract
Background 
CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) accounts for 5–10% of DLBCL cases and has poor patient outcomes. However, most studies on CD5+ DLBCL were performed in Japanese patients and only few data are available for Korean population. In this study, we investigated the clinical characteristics and prognostic impact of CD5 expression in Korean patients with bone marrow (BM) involvement of DLBCL.
Methods 
Patients who were initially diagnosed with BM involvement of de novo DLBCL from 2005 to 2013 were included. Clinicopathological features and outcomes of patients were compared between CD5+ and CD5 negative (CD5-) DLBCL.
Results
Among a total of 57 patients, the number of patients with CD5+ and CD5- DLBCL were 13 and 44, respectively. Clinical and laboratory features of CD5+ DLBCL were not significantly different from those of CD5- DLBCL. The 3-year overall survival (OS) rates for CD5+ and CD5- DLBCL were 20.2% and 59.0%, respectively (P =0.031), and 3-year progression- free survival (PFS) rates for CD5+ and CD5- DLBCL were 23.1% and 50.1%, respectively (P=0.055).
Conclusion
CD5+ DLBCL with BM involvement showed an inferior survival tendency compared to CD5- DLBCL, and thorough evaluation of CD5 expression might be helpful to predict the prognosis of patients with DLBCL.
Keywords: Diffuse large B-cell lymphoma, CD5, Bone marrow, Korea


e-submission

This Article

Current Issue

ba_link01

Indexed/Covered by

Today : 234  /
Total : 39,487